Gan & Lee’s GRADUAL-3 Study Meets Primary Endpoint for Weight Maintenance
Gan & Lee Pharmaceuticals said its GRADUAL-3 study of once-monthly bofanglutide maintenance therapy met its primary endpoint in weight control and maintenance over 24 weeks.
Gan & Lee Pharmaceuticals said its GRADUAL-3 study of once-monthly bofanglutide maintenance therapy met its primary endpoint in weight control and maintenance over 24 weeks.